Close
FINDING CURES TOGETHER<sup>SM</sup>

Advances in Ovarian Cancer Research

​Program 

Friday, Sept. 13, 2019

Saturday, Sept. 14, 2019

Sunday, Sept. 15, 2019

Monday, Sept. 16, 2019


Friday, Sept. 13, 2019

Opening Keynote Session
6-7:30 p.m.

Title to be announced
George Coukos, Ludwig Center for Cancer Research, University of Lausanne, Lausanne, Switzerland


Welcome Reception
7:30-9:30 p.m.


Saturday, Sept. 14, 2019

Continental Breakfast
7-8 a.m.


Plenary Session 1: Drug Resistance and Acquired Vulnerabilities
8-10 a.m.

DNA repair gene promoter methylation patterns adapt and influence PARP inhibitor response
Clare L. Scott, Walter & Eliza Hall Institute of Medicine Research, Parkville, VIC, Australia

Title to be announced
Dipanjan Chowdhury, Dana-Farber Cancer Institute, Boston, Massachusetts

Drug resistance in end-stage high grade serous ovarian cancer
Elizabeth Christie, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia


Break
10-10:30 a.m.


Plenary Session 2: Exceptional Responders
10:30 a.m.-12:30 p.m.

Title to be announced
David D.L. Bowtell, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

Title to be announced
Michael J. Birrer, University of Alabama Comprehensive Cancer Center, Birmingham, Alabama

Insights into exceptional response to high-grade, advanced stage ovarian cancer
Celeste “Leigh” Pearce, University of Michigan School of Public Health, Ann Arbor, Michigan

Understanding disease biology by investigating exceptional responders
Stéphanie Lheureux, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada


Free Time (Lunch on Own)
12:30-3 p.m.


Plenary Session 3: Risk, Prevention, and Early Detection
3-5 p.m.

Management of ovarian cancer risk
Barbara Norquist, University of Washington, Seattle, Washington

Traditional and modern approaches for prevention and early detection
Douglas A. Levine, Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York

Title to be announced
Karen H. Lu, The University of Texas MD Anderson Cancer Center, Houston, Texas

The Ovarian Tumour Tissue Analysis Consortium: Stratification of Prognosis in Ovarian Tumours (OTTA-SPOT) signature for high grade serous ovarian cancer
Susan J. Ramus, University of New South Wales, Sydney, Australia


Poster Session A / Reception
5-7:30 p.m.


Top of page


Sunday, Sept. 15, 2019

Continental Breakfast
7-8 a.m.


Plenary Session 4: Organoids and Model Systems
8-10 a.m.

Title to be announced
David G. Huntsman, University of British Columbia, Vancouver, BC, Canada

Title to be announced
Kathleen R. Cho, University of Michigan Medical School, Ann Arbor, Michigan

Title to be announced
Alan D. D’Andrea, Dana-Farber Cancer Institute, Boston, Massachusetts

Modeling the tumor microenvironment models of high grade serous ovarian cancer
Frances R. Balkwill, Barts Cancer Institute, London, United Kingdom


Break
10-10:30 a.m.


Plenary Session 5: Tumor Microenvironment
10:30 a.m.-12:30 p.m.

ER stress responses shape the ovarian cancer immune-microenvironment
Juan R. Cubillos-Ruiz, Weill Cornell Medical College, New York, New York

Integrating immunotherapy and targeted therapies in cancer treatment: From mouse models to human therapies
Jean J. Zhao, Dana-Farber Cancer Institute, Boston, Massachusetts

Metabolic impact on cancer immunity
Weiping Zou, University of Michigan, Ann Arbor, Michigan

Additional speaker to be announced


Poster Session B / Lunch
12:30-3:30 p.m.


Plenary Session 6: Immunotherapy
3:30-6 p.m.

Immunotherapy in ovarian cancer: Challenges and novel opportunities
Dmitriy Zamarin, Memorial Sloan Kettering Cancer Center, New York, New York

Title to be announced
Lana E. Kandalaft, Ludwig Center for Cancer Research, University of Lausanne, Lausanne, Switzerland

2 additional speakers to be announced


Evening on Own
6 p.m.-


Saturday, Sept. 16, 2019

Continental Breakfast
7-8 a.m.


Plenary Session 7: Rare Tumors
8-10 a.m.

Structure and function of mammalian SWI/SNF chromatin remodeling complexes in human cancer
Cigall Kadoch, Dana-Farber Cancer Institute, Boston, Massachusetts

Therapeutic approaches for ARID1A-mutated ovarian cancer
Rugang Zhang, University of Pennsylvania, Philadelphia, Pennsylvania

Low-grade serous ovarian cancer: Recent advances and future directions
Rachel N. Grisham, Memorial Sloan Kettering Cancer Center, New York, New York

Additional speaker to be announced


Break
10-10:15 a.m.


Plenary Session 8: Bench to Bedside – Gaps / Needs Panel Discussion
10:15 a.m.-12:15 p.m.

Speakers to be announced


Departure
12:15 p.m.


Top of page